Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction – PROMISE

Background Randomised controlled trials have shown that benralizumab, an anti-interleukin-5 receptor monoclonal antibody, reduces exacerbations and oral corticosteroid dose and improves asthma control and lung function in severe eosinophilic asthma. The aim of this study was to confirm results of ra...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Florence Schleich, Catherine Moermans, Laurence Seidel, Céline Kempeneers, Gilles Louis, Florence Rogister, Sophie Tombu, Laurence Pottier, Anne-Lise Poirrier, Stéphanie Ziant, Monique Henket, Carole Sanchez, Virginie Paulus, Françoise Guissard, Anne-Françoise Donneau, Renaud Louis
Format:	Artigo
Jezik:	Inglês
Izdano:	European Respiratory Society 2023-11-01
Serija:	ERJ Open Research
Online dostop:	http://openres.ersjournals.com/content/9/6/00383-2023.full
Oznake:	Označite Brez oznak, prvi označite!